Zobrazeno 1 - 10
of 520
pro vyhledávání: '"Brent K Hollenbeck"'
Autor:
Christopher P. Dall, Xiu Liu, Kassem S. Faraj, Arnav Srivastava, Samuel R. Kaufman, Nicholas Hartman, Vahakn B. Shahinian, Brent K. Hollenbeck
Publikováno v:
Cancer Medicine, Vol 13, Iss 23, Pp n/a-n/a (2024)
ABSTRACT Introduction and Objectives Prior work has demonstrated racial disparities in surgical outcomes for solid organ cancers. We sought to assess the relationship between hospital quality and racial disparities in achievement of textbook outcomes
Externí odkaz:
https://doaj.org/article/12e553a0f4c441e4899b12269d3ce4c5
Autor:
Ted A. Skolarus, Sarah T. Hawley, Jane Forman, Anne E. Sales, Jordan B. Sparks, Tabitha Metreger, Jennifer Burns, Megan V. Caram, Archana Radhakrishnan, Lesly A. Dossett, Danil V. Makarov, John T. Leppert, Jeremy B. Shelton, Kristian D. Stensland, Jennifer Dunsmore, Steven Maclennan, Sameer Saini, Brent K. Hollenbeck, Vahakn Shahinian, Daniela A. Wittmann, Varad Deolankar, S. Sriram
Publikováno v:
Implementation Science Communications, Vol 5, Iss 1, Pp 1-13 (2024)
Abstract Background Many men with prostate cancer will be exposed to androgen deprivation therapy (ADT). While evidence-based ADT use is common, ADT is also used in cases with no or limited evidence resulting in more harm than benefit, i.e., overuse.
Externí odkaz:
https://doaj.org/article/edf770c1937947e5bba9b2a128e51551
Autor:
Xinyu Liang, Ziwei Zhu, Kassem Faraj, Vahakn B. Shahinian, Brent K. Hollenbeck, Lindsey A. Herrel
Publikováno v:
Cancer Medicine, Vol 13, Iss 14, Pp n/a-n/a (2024)
Abstract Introduction Dual eligible beneficiaries are a vulnerable population who often experience inferior access to care and outcomes compared to non‐dual eligible beneficiaries. The Oncology Care Model (OCM) is an alternative payment model that
Externí odkaz:
https://doaj.org/article/4db64d667e6f43eba76ead21f42a2c8b
Autor:
Megan E. V. Caram, Kyle Kumbier, Phoebe A. Tsao, Jennifer Burns, Jordan B. Sparks, Kristian D. Stensland, Zachery R. Reichert, Joshi J. Alumkal, Brent K. Hollenbeck, Vahakn Shahinian, Alexander Tsodikov, Ted A. Skolarus
Publikováno v:
Cancer Medicine, Vol 13, Iss 12, Pp n/a-n/a (2024)
Abstract Introduction Metastatic castration‐resistant prostate cancer (mCRPC) is a heterogeneous disease with prognoses varying from months to years at time of castration‐resistant diagnosis. Optimal first‐line therapy for those with different
Externí odkaz:
https://doaj.org/article/e87d252553e64f07b78df5cbebfcca3e
Autor:
Kassem S. Faraj, Samuel R. Kaufman, Lindsey A. Herrel, Avinash Maganty, Mary Oerline, Megan E. V. Caram, Vahakn B. Shahinian, Brent K. Hollenbeck
Publikováno v:
Cancer Medicine, Vol 12, Iss 24, Pp 22325-22332 (2023)
Abstract Introduction Some worry that physician practices acquired by private equity may increase the use of services to maximize revenue. We assessed the effects of private equity acquisition on spending, use of treatment, and diagnostic testing in
Externí odkaz:
https://doaj.org/article/63873959c5394b72920fa809b8c1255b
Autor:
Noah Krampe, Samuel R. Kaufman, Mary K. Oerline, Dawson Hill, Megan E. V. Caram, Vahakn B. Shahinian, Brent K. Hollenbeck, Avinash Maganty
Publikováno v:
Cancer Medicine, Vol 12, Iss 16, Pp 17346-17355 (2023)
Abstract Background Despite clinical guidelines advocating for use of conservative management in specific clinical scenarios for men with prostate cancer, there continues to be tremendous variation in its uptake. This variation may be amplified among
Externí odkaz:
https://doaj.org/article/68511507ff54470788d267bd51b9187a
Autor:
Avinash Maganty, Samuel R. Kaufman, Mary K. Oerline, Kassem S. Faraj, Megan E. V. Caram, Vahakn B. Shahinian, Brent K. Hollenbeck
Publikováno v:
Cancer Medicine, Vol 13, Iss 1, Pp n/a-n/a (2024)
Abstract Objective To examine the effect of urologist participation in value‐based payment models on the initial management of men with newly diagnosed prostate cancer. Methods Medicare beneficiaries with prostate cancer diagnosed between 2017 and
Externí odkaz:
https://doaj.org/article/fd854d2fc477459791dcc0a0ee327001
Autor:
Megan E. V. Caram, Kyle Kumbier, Jennifer Burns, Jordan B. Sparks, Phoebe A. Tsao, Kristian D. Stensland, Samuel L. Washington III, Brent K. Hollenbeck, Vahakn Shahinian, Ted A. Skolarus
Publikováno v:
Cancer Medicine, Vol 12, Iss 6, Pp 6945-6955 (2023)
Abstract Background Over the past decade, abiraterone and enzalutamide have largely replaced ketoconazole as oral treatments for castration‐resistant prostate cancer (CRPC). We investigated the differential adoption of abiraterone and enzalutamide
Externí odkaz:
https://doaj.org/article/8e7c0dabb2ab4edb91d46c692eb5454b
Autor:
Ted A. Skolarus, Jane Forman, Jordan B. Sparks, Tabitha Metreger, Sarah T. Hawley, Megan V. Caram, Lesly Dossett, Alan Paniagua-Cruz, Danil V. Makarov, John T. Leppert, Jeremy B. Shelton, Kristian D. Stensland, Brent K. Hollenbeck, Vahakn Shahinian, Anne E. Sales, Daniela A. Wittmann
Publikováno v:
Implementation Science Communications, Vol 2, Iss 1, Pp 1-16 (2021)
Abstract Background Men with prostate cancer are often treated with the suppression of testosterone through long-acting injectable drugs termed chemical castration or androgen deprivation therapy (ADT). In most cases, ADT is not an appropriate treatm
Externí odkaz:
https://doaj.org/article/b6afa2d9261f4c2c8d1d29864c3c98e6
Autor:
Ted A. Skolarus, Jane Forman, Jordan B. Sparks, Tabitha Metreger, Sarah T. Hawley, Megan V. Caram, Lesly Dossett, Alan Paniagua-Cruz, Danil V. Makarov, John T. Leppert, Jeremy B. Shelton, Kristian D. Stensland, Brent K. Hollenbeck, Vahakn Shahinian, Anne E. Sales, Daniela A. Wittmann
Publikováno v:
Implementation Science Communications, Vol 4, Iss 1, Pp 1-1 (2023)
Externí odkaz:
https://doaj.org/article/b8bf610d59714ac18efd76a830a52e26